Table 4.
Efficacy data in the subgroup of patients that required concomitant medications.
| T0 | T1 | T3 | T6 | P-value | |
|---|---|---|---|---|---|
| Platelet count, × 109/:L | 8 | 21 | 42 | 100 | <0.0001 |
| Median (range) | (1–51) | (1–668) | (1–272) | (2–863) | |
| Patients with a platelet count of at least 30 × 109/L, n°/TOT (%) | 7/32 (22) | 16/32 (50) | 17/31 (55) | 16/25 (64) | <0.0001 |
| Patients with a platelet count of at least 100 × 109/L, n°/ TOT (%) | 0/32 (0) | 6/32 (19) | 10/31 (32) | 12/25 (48) | <0.0001 |
Median platelet count (× 109/L), percentage of patients with a platelet count ≥30 × 109/L, percentage of patients with a platelet count ≥100 × 109/L at the start of therapy (T0); after 1 month (T1); after 3 months (T3); after 6 months (T6).